Antibodies that specifically bind alpha klotho
AssigneesThe Governing Council of the University of Toronto, Board of Regents, The University of Texas System
InventorsSachdev S. Sidhu, Sarah L. Barker, Orson W. Moe, Makoto Kuro-o, Johanne Pastor
Life of this patent
Estimating the term…
Abstract
An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining region (CDR) CDR-L3 and the heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3, with the amino acid sequences of said CDRs comprising one or more of the sequences set forth below: CDR-L3; selected from any one of SEQ ID NOs: 123, 126-130, 142, 148 or 149; CDR-H1: SEQ ID NOs: 121 or 124; CDR-H2; SEQ ID NOs: 122 or 125; and/or CDR-H3: selected from any one of SEQ ID NOs: 196-226.
Claims14
An antibody or binding fragment thereof that specifically binds an αKlotho polypeptide, wherein the antibody or binding fragment thereof comprises:
- a light chain variable (VL) domain, wherein the VL domain comprises a complementarity determining region (CDR) L1, a CDR-L2 and a CDR-L3;
- and
- a heavy chain variable (VH) domain, wherein the VH domain comprises a CDR-H1, a CDR-H2 and a CDR-H3;
- and wherein the VL and VH domains are selected from the group consisting of:
- (i) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQYSYYYASPIT (SEQ ID NO:
- 155), respectively;
- and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNIYSSS (residues 1 to 8 of SEQ ID NO:
- 173),
- IYPYSGYT (residues 2 to 9 of SEQ ID NO:
- 193), and
- ARYSWGSSFWPGYGFDY (SEQ ID NO:
- 223), respectively;
- (ii) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQYSWYWYSPIT (SEQ ID NO:
- 154), respectively;
- and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNIYYSS (residues 1 to 8 of SEQ ID NO:
- 172),
- IYPYYSYT (residues 2 to 9 of SEQ ID NO:
- 192), and
- ARSVASALDY (SEQ ID NO:
- 222), respectively;
- (iii) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQGSYYWWSPIT (SEQ ID NO:
- 150), respectively, and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNIYSYS (residues 1 to 8 of SEQ ID NO:
- 169),
- IYPSSSYT (residues 2 to 9 of SEQ ID NO:
- 185), and
- ARAGYFSAYYSSWGAMDY (SEQ ID NO:
- 211), respectively;
- and
- (iv) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQSSPPIT (SEQ ID NO:
- 148), respectively;
- and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNLYSYS (residues 1 to 8 of SEQ ID NO:
- 167),
- ISPYSGYT (residues 2 to 9 of SEQ ID NO:
- 184), and
- ARSFFPYSYWVYGGGMDY (SEQ ID NO:
- 206), respectively.
A kit comprising an antibody or binding fragment thereof that specifically binds an αKlotho polypeptide, and a reference agent,
- wherein the antibody or binding fragment thereof comprises:
- a light chain variable (VL) domain, wherein the VL domain comprises a complementarity determining region (CDR) L1, a CDR-L2 and a CDR-L3;
- and
- a heavy chain variable (VH) domain, wherein the VH domain comprises a CDR-H1, a CDR-H2 and a CDR-H3;
- and wherein the VL and VH domains are selected from the group consisting of:
- (i) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQYSYYYASPIT (SEQ ID NO:
- 155), respectively;
- and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNIYSSS (residues 1 to 8 of SEQ ID NO:
- 173),
- IYPYSGYT (residues 2 to 9 of SEQ ID NO:
- 193), and
- ARYSWGSSFWPGYGFDY (SEQ ID NO:
- 223), respectively;
- (ii) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQYSWYWYSPIT (SEQ ID NO:
- 154), respectively;
- and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNIYYSS (residues 1 to 8 of SEQ ID NO:
- 172),
- IYPYYSYT (residues 2 to 9 of SEQ ID NO:
- 192), and
- ARSVASALDY (SEQ ID NO:
- 222), respectively;
- (iii) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQGSYYWWSPIT (SEQ ID NO:
- 150), respectively, and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNIYSYS (residues 1 to 8 of SEQ ID NO:
- 169),
- IYPSSSYT (residues 2 to 9 of SEQ ID NO:
- 185), and
- ARAGYFSAYYSSWGAMDY (SEQ ID NO:
- 211), respectively;
- (iv) a VL domain wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise amino acid sequences:
- QSVSSA (SEQ ID NO:
- 140),
- SAS (SEQ ID NO:
- 141), and
- QQSSPPIT (SEQ ID NO:
- 148), respectively;
- and
- a VH domain wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences:
- GFNLYSYS (residues 1 to 8 of SEQ ID NO:
- 167),
- ISPYSGYT (residues 2 to 9 of SEQ ID NO:
- 184), and
- ARSFFPYSYWVYGGGMDY (SEQ ID NO:
- 206), respectively.
An antibody or binding fragment thereof that specifically binds an αKlotho polypeptide, wherein the antibody or binding fragment thereof comprises:
- a light chain variable (VL) domain, wherein the VL domain comprises a complementarity determining region (CDR) L1, a CDR-L2 and a CDR-L3, and wherein the CDR-L1, the CDR-L2 and the CDR-L3 comprise the amino acid sequences QSVSSA (SEQ ID NO:
- 140), SAS (SEQ ID NO:
- 141), and QQYSYYYASPIT (SEQ ID NO:
- 155), respectively;
- and
- a heavy chain variable (VH) domain, wherein the VH domain comprises a CDR-H1, a CDR-H2 and a CDR-H3;
- and wherein the CDR-H1, the CDR-H2 and the CDR-H3 comprise amino acid sequences GFNIYSSS (residues 1 to 8 of SEQ ID NO:
- 173), IYPYSGYT (residues 2 to 9 of SEQ ID NO:
- 193), and ARYSWGSSFWPGYGFDY (SEQ ID NO:
- 223), respectively.
Dependencies are inferred from the claim text.